Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2017 Oct 24

PMID 29057817

Citations 33

Authors

Sang Won Jeon

Yong-Ku Kim

Affiliations

Soon will be listed here.

Abstract

Atypical antipsychotics (AAP) are the prevailing form of schizophrenia treatment today due to their low side effects and superior efficacy. Nevertheless, some issues still need to be addressed. First, there are still a large number of patients with treatment-resistant schizophrenia (TRS), which has led to a growing trend to resort to AAP polypharmacy with few side effects. Most clinical treatment guidelines recommend clozapine monotherapy in TRS, but around one third of schizophrenic patients fail to respond to clozapine. For these patients, with clozapine-resistant schizophrenia AAP polypharmacy is a common strategy with a continually growing evidence base. Second, AAP generally have great risks for developing metabolic syndrome, such as weight gain, abnormality in glucose, and lipid metabolism. These metabolic side effects have become huge stumbling blocks in today's schizophrenia treatment that aims to improve patients' quality of life as well as symptoms. The exact reasons why this particular syndrome occurs in patients treated with AAP is as yet unclear though factors such as interaction of AAP with neurotransmitter receptors, genetic pholymorphisms, type of AAPs, length of AAP use, and life style of schizophrenic patients that may contribute to its development. The present article aimed to review the evidence underlying these key issues and provide the most reasonable interpretations to expand the overall scope of antipsychotics usage.

Citing Articles

Atypical antipsychotic drugs cause abnormal glucose and lipid metabolism independent of weight gain.

Yang Y, Wu R Eur Arch Psychiatry Clin Neurosci. 2025; .

PMID: 39969542 DOI: 10.1007/s00406-025-01965-6.

Guideline for pharmacological treatment of schizophrenia 2022.

Neuropsychopharmacol Rep. 2024; 45(1):e12497.

PMID: 39587785 PMC: 11666347. DOI: 10.1002/npr2.12497.

Methylome-wide and meQTL analysis helps to distinguish treatment response from non-response and pathogenesis markers in schizophrenia.

Polakkattil B, Vellichirammal N, Nair I, Nair C, Banerjee M Front Psychiatry. 2024; 15:1297760.

PMID: 38516266 PMC: 10954811. DOI: 10.3389/fpsyt.2024.1297760.

Prevalence and prescribers' knowledge of psychotropic polypharmacy in the Bono, Bono East, and Ahafo Regions, Ghana.

Dumba J, Barimah A, Ibrahim M, Allotey S, Alorvi S, Appertey W Heliyon. 2024; 10(2):e24243.

PMID: 38293502 PMC: 10825345. DOI: 10.1016/j.heliyon.2024.e24243.

Relationships Between Adherence to Guideline Recommendations for Pharmacological Therapy Among Clinicians and Psychotic Symptoms in Patients With Schizophrenia.

Kodaka F, Ohi K, Yasuda Y, Fujimoto M, Yamamori H, Hasegawa N Int J Neuropsychopharmacol. 2023; 26(8):557-565.

PMID: 37381793 PMC: 10464927. DOI: 10.1093/ijnp/pyad037.

References

Torniainen M, Mittendorfer-Rutz E, Tanskanen A, Bjorkenstam C, Suvisaari J, Alexanderson K . Antipsychotic treatment and mortality in schizophrenia. Schizophr Bull. 2014; 41(3):656-63. PMC: 4393693. DOI: 10.1093/schbul/sbu164. View

Casey D . Dyslipidemia and atypical antipsychotic drugs. J Clin Psychiatry. 2004; 65 Suppl 18:27-35. View

Fleischhacker W, Heikkinen M, Olie J, Landsberg W, Dewaele P, McQuade R . Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol. 2010; 13(8):1115-25. DOI: 10.1017/S1461145710000490. View

Taniguchi A, Nakai Y, Fukushima M, Kawamura H, Imura H, Nagata I . Pathogenic factors responsible for glucose intolerance in patients with NIDDM. Diabetes. 1992; 41(12):1540-6. DOI: 10.2337/diab.41.12.1540. View

Potkin S, Thyrum P, Alva G, Bera R, Yeh C, Arvanitis L . The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine. J Clin Psychopharmacol. 2002; 22(2):121-30. DOI: 10.1097/00004714-200204000-00004. View

De Hert M, Cohen D, Bobes J, Cetkovich-Bakmas M, Leucht S, Ndetei D . Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level. World Psychiatry. 2011; 10(2):138-51. PMC: 3104888. DOI: 10.1002/j.2051-5545.2011.tb00036.x. View

Silvestre J, Prous J . Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005; 27(5):289-304. DOI: 10.1358/mf.2005.27.5.908643. View

Rocha F, Hara C . Benefits of combining aripiprazole to clozapine: three case reports. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(6):1167-9. DOI: 10.1016/j.pnpbp.2006.03.024. View

Xiang Y, Wang C, Si T, Lee E, He Y, Ungvari G . Antipsychotic polypharmacy in inpatients with schizophrenia in Asia (2001-2009). Pharmacopsychiatry. 2011; 45(1):7-12. DOI: 10.1055/s-0031-1286345. View

10.

Kelly A, Sheitman B, Hamer R, Rhyne D, Reed R, Graham K . A naturalistic comparison of the long-term metabolic adverse effects of clozapine versus other antipsychotics for patients with psychotic illnesses. J Clin Psychopharmacol. 2014; 34(4):441-5. DOI: 10.1097/JCP.0000000000000159. View

11.

Wysokinski A . Blood levels of glucose and insulin and insulin resistance in patients with schizophrenia on clozapine monotherapy. Diabetes Metab Syndr. 2014; 8(4):236-41. DOI: 10.1016/j.dsx.2014.09.020. View

12.

Pompili M, Ruberto A, Kotzalidis G, Girardi P, Tatarelli R . Suicide and awareness of illness in schizophrenia: an overview. Bull Menninger Clin. 2005; 68(4):297-318. DOI: 10.1521/bumc.68.4.297.56643. View

13.

Kang S, Lee J, Han H, Soh M, Hong J . Polymorphisms of the leptin and HTR2C genes and clozapine-induced weight change and baseline BMI in patients with chronic schizophrenia. Psychiatr Genet. 2014; 24(6):249-56. DOI: 10.1097/YPG.0000000000000053. View

14.

Melkersson K, Jansson E . Effects of the atypical antipsychotic clozapine on insulin release in vitro. Neuro Endocrinol Lett. 2007; 28(6):854-60. View

15.

Panariello F, Polsinelli G, Borlido C, Monda M, De Luca V . The role of leptin in antipsychotic-induced weight gain: genetic and non-genetic factors. J Obes. 2012; 2012:572848. PMC: 3317122. DOI: 10.1155/2012/572848. View

16.

. Combination and high-dose atypical antipsychotic therapy in patients with schizophrenia: systematic review. CADTH Technol Overv. 2012; 2(3):e2301. PMC: 3442617. View

17.

Freudenreich O, Henderson D, Walsh J, Culhane M, Goff D . Risperidone augmentation for schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled trial. Schizophr Res. 2007; 92(1-3):90-4. DOI: 10.1016/j.schres.2006.12.030. View

18.

Ranjan R, Meltzer H . Acute and long-term effectiveness of clozapine in treatment-resistant psychotic depression. Biol Psychiatry. 1996; 40(4):253-8. DOI: 10.1016/0006-3223(95)00305-3. View

19.

Josiassen R, Joseph A, Kohegyi E, Stokes S, Dadvand M, Paing W . Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2004; 162(1):130-6. DOI: 10.1176/appi.ajp.162.1.130. View

20.

Correll C, Shaikh L, Gallego J, Nachbar J, Olshanskiy V, Kishimoto T . Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011; 131(1-3):58-62. PMC: 3159758. DOI: 10.1016/j.schres.2011.02.016. View